Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07516067

Spinal Cord Stimulation for Children With Cerebral Palsy

The goal of this clinical trial is to help understand spinal cord excitability in children with cerebral palsy compared to neurologically typical children. The main questions it aims to answer are:

* What are the mechanisms of spinal circuit hyperexcitability in CP? * Can transcutaneous spinal cord stimulation reduce spinal circuit hyperexcitability?

Participants with cerebral palsy will be asked to complete:

* Movement and strength exercises * Mild, non-invasive stimulation on the back and legs that feels like a light tap. * Gentle, non-invasive tests that help us see how the brain and the spinal cord communicate with the muscles

Recruiting

Interested in participating?

Request Info

Key information

Age range

5 year–17 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

UPMC Children's Hospital of Pittsburgh

Pittsburgh, Pennsylvania, 15224, United States

Location status: Recruiting

Location contact

Amit Sinha, MD

SUB_INVESTIGATOR

Bailey McDonald, BS

CONTACT

[email protected]

412-692-9966

Genis Prat-Ortega, PhD

SUB_INVESTIGATOR

George Wittenberg, MD, PhD

SUB_INVESTIGATOR

Martin G Piazza, MD

CONTACT

[email protected]

Martin G Piazza, MD

PRINCIPAL_INVESTIGATOR

Taylor Abel, MD

SUB_INVESTIGATOR

About this study

This is a clinical trial designed to evaluate spinal circuit hyperexcitability in children with cerebral palsy (CP) and to explore the potential of transcutaneous spinal cord stimulation (tSCS) to reduce excitability and improve spasticity. The investigators will also examine the mechanisms underlying this potential reduction of spinal hyperexcitability.

The investigators will non-invasively record a range of electrophysiological responses using surface electrodes while participants perform isometric tasks. These recordings will help to better understand the differences in spinal excitability between children with CP and typically developing peers and will provide early insight into how tSCS might modulate these responses.

This study has two aims: The first aim is to evaluate spinal circuit excitability in Children with CP and in children without neurological conditions (controls). Several electrophysiological markers will be collected, including sensory reflex responses, reciprocal inhibition, motoneuron firing patterns, and motor evoked potential by transcranial magnetic stimulation. The second aim is to assess the impact of tSCS on spasticity and hypertonia in CP. To achieve this aim, the same electrophysiological measurements of spinal excitability will be repeated during non-invasive transcutaneous spinal cord stimulation in patient-participants (children with CP).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

A. Patient-Participant Group (Children with Cerebral Palsy)

  • Children aged 5 to 17 years with a confirmed diagnosis of cerebral palsy.
  • Gross Motor Function Classification System (GMFCS) Levels I to IV, able to walk with or without assistance (walker or cane). This classification will have been completed by Dr. Martin Piazza and his Movement Disorders clinic team.
  • Stable medical condition without recent surgeries or interventions that could affect motor function.
  • Must be able to communicate basic needs and follow simple instructions.
  • Provision of informed consent by a parent or legal guardian, with assent from the child as appropriate.

B. Control Group (Children without Neurological Diagnoses)

  • Children aged 5 to 17 years with no history of neurological diagnoses.
  • Must be fully ambulatory without assistance.
  • Must be able to communicate basic needs and follow simple instructions.
  • Provision of informed consent by a parent or legal guardian, with assent from the child as appropriate.

Exclusion criteria

  • Presence of implanted medical devices (e.g., baclofen pumps, deep brain stimulators) that may interfere with TSCS.
  • Severe scoliosis or spinal deformities that could affect the delivery of tSCS.
  • Uncontrolled epilepsy or a history of frequent seizures.
  • Severe cognitive impairments limiting the ability to comply with study procedures.
  • Skin conditions or open wounds at the site of stimulation.
  • Participation in other interventional studies that may confound results.
  • Any serious disease or disorder (e.g. cancer, severe cardiac or respiratory disease, etc.) that could affect ability to participate in this study.

Treatment and study plan

Transcutaneous Spinal Cord Stimulation (tSCS)

Device

Transcutaneous spinal cord stimulation (tSCS) will be administered using the Digitimer DS8R Biphasic Constant Current Stimulator, an external isolated stimulator system used in human research. The DS8R delivers controlled electrical pulses with adjustable stimulation parameters.

tSCS will be delivered at frequencies between 30-50 Hz with 1 ms pulse width and a biphasic waveform. Self-adhesive surface electrodes will be positioned longitudinally over the thoracolumbar region at T11-L1 (cathodes) and over the iliac crests (anodes).

In children with cerebral palsy, electrophysiological and clinical assessments will be conducted before, during, and after stimulation to evaluate changes in spinal excitability, spasticity, and motor function. Stimulation is administered during supervised study visits.

Primary outcomes

  1. Change in H-reflex with Transcutaneous Spinal Cord Stimulation

    Time frame: Measured during 1 of up to 3 research sessions over up to 16 weeks

    The primary outcome is H-reflex peak-to-peak amplitude with transcutaneous spinal cord stimulation (tSCS).

    Success criteria is measured as a reduction in 20 percent of peak-to-peak amplitude of the H-reflex.

  2. Modified Ashworth Scale

    Time frame: Measured during 1 of up to 3 research sessions over up to 16 weeks

    The primary outcome is the spasticity measured by the Modified Ashworth Scale with and without tSCS. The Modified Ashworth Scale is used to assess muscle spasticity. The scale is as follows:

    0 = No increase in muscle tone;

    1 = Slight increase in tone giving a catch when the limb is moved in flexion or extension;

    1+ = Slight increase in muscle tone, indicated by a catch followed by minimal resistance throughout range of motion (ROM); 2 = More marked increase in tone through most of the ROM, but the limb easily flexed; 3 = Considerable increase in tone, passive movement difficult; 4 = Limb rigid in flexion or extension;

    Higher scores represent greater spasticity. Success criteria is measured as a reduction of at least 1 point in average across muscles. Scores will be averaged across assessed muscle groups to calculate a mean Modified Ashworth Scale score for each participant.

Secondary outcomes

  1. TMS motor evoked potential

    Time frame: Measured during 1 of up to 3 research sessions over up to 16 weeks

    A reduction in TMS motor evoked potential with tSCS is expected. Success criteria is measured as a decrease in 20 percent of the peak-to-peak amplitude with tSCS.

  2. Reciprocal inhibition between antagonist muscles with tSCS

    Time frame: Measured during 1 of up to 3 research sessions over up to 16 weeks

    Reciprocal inhibition will be tested by conditioning the H-reflex (elicited by stimulating at the tibial nerve) with a prior (between 1 and 5 ms) stimulation of the deep peroneal nerve. The results will be compared in CP vs control to determine its contribution in spinal hyperexcitability in CP. Additionally, the effect of tSCS in CP will be compared to determine whether tSCS can normalize hyperexcitability in CP. Success criteria is measured as a change in reciprocal inhibition of 20 percent towards the values in control participants.

  3. Motoneuron excitability

    Time frame: Measured during 1 of up to 3 research sessions over up to 16 weeks

    The investigators will measure the persistent inward currents of motoneurons as a measure of motoneuron excitability . A reduction in persistent inward current with tSCS is expected. The investigators will compare the results in CP vs control to determine its contribution in spinal hyperexcitability in CP. Additionally, the effect of tSCS in CP will be compared to determine whether tSCS can normalize hyperexcitability in CP. Success criteria is measured as a change in motoneuron excitability of 20 percent towards the values obtained in control participants.

Study contacts

Contact information is provided by the study sponsor or research team.

Bailey McDonald, BS

CONTACT

[email protected]

412-692-9966

Martin G Piazza, MD

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Martin Piazza

Other

Registry information

Official study title

Transcutaneous Spinal Cord Stimulation to Treat Spasticity in Children With Cerebral Palsy

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Apr 7, 2026
Registry last updated
Apr 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.